

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSIDE INFORMATION ANNOUNCEMENT ARBITRATION AWARD

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance of Hong Kong.

(I) BASIC INFORMATION OF THE ARBITRATION

On 20 July 2026, the Company received the Arbitration Award [2026] CIETAC Beijing Arbitration No. 1519 rendered by the China International Economic and Trade Arbitration Commission. The arbitration arose from the guarantee arrangements under the 2020 asset transaction project entered into between the Company and the relevant entities of Beijing Konruns Pharmaceutical Co., Ltd. in 2020, and the relevant equity transfer was completed in 2020.

The above Award ruled that the Company and the relevant jointly liable parties are required to pay liquidated damages, relevant fees and arbitration fee allocations in the aggregate amount of approximately RMB92,000,000. The Company has significant objections to the Award, and has engaged a compliance legal service team to initiate statutory procedures including applying to set aside the Award.

(II) EXPLANATION OF THE IMPACT ON THE GROUP

Currently, the Award remains within the statutory period in which an application to set aside the Award may be made in accordance with the law, and the relevant payment obligations have not entered the stage of compulsory enforcement. The Group is conducting a prudent assessment of the relevant potential financial impact in conjunction with the liability allocation arrangements among the jointly liable parties and the liability boundary of the entity that has completed bankruptcy restructuring. The Group’s daily operations and cash flow are currently maintained in a normal state.

The Company will continue to follow up on the progress of such matter and fulfil subsequent information disclosure obligations in a timely manner in accordance with the requirements of the Listing Rules. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 18 August 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.